title: Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study.
abstract: BACKGROUND
  Long-term maintenance treatment with an antipsychotic is often required to prevent relapse and mitigate functional deterioration in patients with schizophrenia.
  
  
  OBJECTIVE
  This study assessed the long-term safety, tolerability, and maintenance of the therapeutic effect of aripiprazole once-monthly 400 mg (AOM 400) in patients with schizophrenia.
  
  
  METHODS
  This 52-week, open-label study included patients previously enrolled in 1 of 2 AOM 400 randomized controlled trials (RCTs) and de novo patients. Safety endpoints included adverse events (AEs), suicidality, extrapyramidal symptoms, injection-site pain, and clinically relevant changes in clinical and laboratory values. The primary efficacy endpoint was the percentage of stable patients at baseline who remained stable at the last visit of the AOM 400 maintenance phase. All endpoints were assessed with descriptive statistics; there were no formal planned statistical analyses.
  
  
  RESULTS
  Of 1,247 patients screened, 1,178 enrolled in the study (194 de novo and 984 patients from the RCTs) and 1,081 received maintenance treatment with AOM 400. The maintenance phase completion rate was 79.4% at 52 weeks. Treatment-emergent AEs in ⩾5% of patients during open-label AOM 400 treatment were headache (7.6%), nasopharyngitis (7.0%), anxiety (6.8%), and insomnia (6.6%). There were no clinically relevant changes in safety parameters of interest. Ninety-five percent of stable patients at baseline remained stable at their last visit during the AOM 400 maintenance phase.
  
  
  CONCLUSIONS
  The long-term safety and tolerability profile of AOM 400 was comparable to the RCTs, and the long-term therapeutic effect was maintained.
authors.affiliation: Global Clinical Development (CNS), Otsuka Pharmaceutical Development & Commercialization, Inc. , Princeton, NJ, USA.
authors.forename: Timothy
authors.initials: T
authors.lastname: Peters-Strickland
authors.affiliation: CNS Global Medical Affairs, Otsuka Pharmaceutical Development & Commercialization, Inc. , Princeton, NJ, USA.
authors.forename: Ross A
authors.initials: RA
authors.lastname: Baker
authors.affiliation: Global Medical, Regulatory Affairs and Alliances, Otsuka America Pharmaceutical Inc. , Princeton, NJ, USA.
authors.forename: Robert D
authors.initials: RD
authors.lastname: McQuade
authors.affiliation: Biometrics, Otsuka Pharmaceutical Development & Commercialization, Inc. , Rockville, MD, USA.
authors.forename: Na
authors.initials: N
authors.lastname: Jin
authors.affiliation: Medical Affairs & Phase IV Clinical Affairs, Lundbeck LLC , Deerfield, IL, USA.
authors.forename: Anna
authors.initials: A
authors.lastname: Eramo
authors.affiliation: Global Clinical Development (CNS), Otsuka Pharmaceutical Development & Commercialization, Inc. , Princeton, NJ, USA.
authors.forename: Pamela
authors.initials: P
authors.lastname: Perry
authors.affiliation: Global Clinical Development (CNS), Otsuka Pharmaceutical Development & Commercialization, Inc. , Princeton, NJ, USA.
authors.forename: Brian R
authors.initials: BR
authors.lastname: Johnson
authors.affiliation: Global Clinical Development (CNS), Otsuka Pharmaceutical Development & Commercialization, Inc. , Rockville, MD, USA.
authors.forename: Anna
authors.initials: A
authors.lastname: Duca
authors.affiliation: Global Clinical Development (CNS), Otsuka Pharmaceutical Development & Commercialization, Inc. , Princeton, NJ, USA.
authors.forename: Raymond
authors.initials: R
authors.lastname: Sanchez